Study sheds light on atypical periprosthetic femoral fractures

October 03, 2018

Following surgery, some patients experience a broken bone around the implants of a total hip replacement--called a periprosthetic femoral fracture. In a study of such patients published in the Journal of Bone and Mineral Research, investigators found that 8.3% of patients had atypical femoral fractures, which are a rare type of femoral stress fracture. The researchers also found a strong association between use of bisphosphonates and risk of atypical femoral fractures.

Previous studies have linked bisphosphonates use to atypical femoral fractures in patients with osteoporosis. However, these are very rare events, which are overwhelmed by the fracture prevention effect of bisphosphonates.

"Fractures around orthopedic implants are becoming increasingly more frequent. Our work shines light on the necessity for clinicians to better identify this subgroup of patients with atypical fractures around a femoral implant as they may benefit from different therapies," said senior author Dr. Etienne Belzile, of CHU de Québec - Université Laval, in Canada.
-end-


Wiley

Related Bisphosphonates Articles from Brightsurf:

Hip fracture risk linked to nanoscale bone inflexibility
New research has highlighted a preventative treatment gap in patients prone to bone fractures who are otherwise healthy.

Bone drug may be beneficial for knee osteoarthritis
Bisphosphonates (a class of drugs that prevent the loss of bone density and used to treat osteoporosis and similar diseases) appear to be safe and beneficial for osteoarthritis patients.

Fracture risk associated with bisphosphonate drug holidays
Bisphosphonates have been shown to reduce the risk of osteoporotic fractures.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

Osteoporosis drugs linked to reduced risk of premature death
A large cohort study has revealed a common osteoporosis drug significantly decreases premature mortality risk, likely related to a reduction in bone loss.

IOF review of impact of drug holidays on bone health
The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new IOF Working Group paper.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Bisphosphonates increasingly prescribed to the women most likely to benefit
In recent years, women who start taking bisphosphonates (BPs) to treat osteoporosis and prevent fracture have trended from younger to older and from having osteopenia to having osteoporosis, researchers report.

US older women three times as likely to be treated for osteoporosis as men
Older women in the US are three times as likely to be treated for osteoporosis as men of the same age, reveals research published online in the Journal of Investigative Medicine.

The delicate balance of treating growing but brittle bones
Turning off a bone receptor protein could potentially treat osteoporosis in children without affecting bone growth.

Read More: Bisphosphonates News and Bisphosphonates Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.